A platform-based IP strategy focused on the “last mile” of therapeutics: getting peptides, biologics and other agents to the tissue where they need to act.
“We believe many promising therapeutic agents are constrained not simply by the molecule, but by the limitations of how that molecule reaches its intended target. Our intellectual property strategy is focused on the delivery problem.”
How Vector’s 15 patent applications are organized, what each area covers, and what it is intended to be used for.
Multi-route technologies for delivering peptides, biologics and other complex agents through non-gastrointestinal and non-traditional pathways, including transdermal, iontophoretic and lyophilized reconstitution-based systems.
Intended use: peptide formulations that are difficult to administer orally or systemically.
Interferential-hybrid iontophoresis systems that combine tissue pre-conditioning, electrically driven therapeutic transport and retention phases.
Intended use: non-invasive delivery to deep musculoskeletal and peripheral nerve targets.
Lyophilized multimodal analgesic compositions, integrated reconstitution kits and localized administration technologies, including atomized catheter-based delivery during surgery.
Intended use: targeted perioperative pain management, the foundation of VectorMist™ and The LASSO Protocol™.
EUS-guided multimodal therapy, microneedle-tipped intratumoral delivery, conductivity- and impedance-guided treatment, transarterial pancreatic delivery and anchored catheter systems.
Intended use: sustained, locoregional delivery of therapy directly to pancreatic tumors.
Non-invasive systems, including peptide-based regenerative technologies, for delivering regenerative agents.
Intended use: musculoskeletal and peripheral nerve repair.
Integrated wound-healing technologies combining responsive therapeutic release, oxygenation, multi-wavelength phototherapy and real-time wound monitoring.
Intended use: automated wound-treatment platforms.
Filings Vector has announced individually, newest first.
A provisional application with the USPTO covering an integrated platform that pairs tissue-repair peptides with the patient’s own platelet-rich plasma or platelet-rich fibrin, with adjunct formulations sequenced so routine orthopedic pain and infection agents interfere less with repair cells.
Intended use: improving tissue healing across orthopedic surgical care.
Read the release →A wearable transdermal platform that uses a pulsed magnetic field to move peptides through the skin.
Intended use: needle-free peptide delivery.
Read the release →A microneedle catheter platform for delivering therapy directly into tumors.
Intended use: intratumoral drug delivery, with an initial focus on pancreatic cancer.
Read the release →Patent applications are pending. Filing does not guarantee issuance, regulatory clearance or commercial success. Sources: Vector press releases of May 1, June 30, July 15 and August 20, 2026.
For licensing, partnership or investor questions about Vector’s patent portfolio, contact our team.